Stock DZ
30.12.2017 kl 00:17


Thank you! Do you think there is a chance that the undisclosed top 10 pharma in the fimanac collaboration will be interested in fimachem too. They already have the insight into the platform via both in vitro and in vivo studies in fimanac plus no other treatment for bile duct recognized yet, so they certainly don’t have a competitive treatment. The timing for agreement renewal within fimanac and the quest for a partner for fimachem coincide at this stage. Could we hope for something here?